中金公司发表研究报告指，三生制药上半年收入43.56亿元，股东应占净利润按年增长24.6%至13.58亿元，经调整净利润按年增长2.1%至11.36亿元，符合市场预期。考虑到业务发展成果带来的收入确认，该行将2025年及26年净利润预测分别上调186.5%和138.3%，至62.49亿元及56.64亿元；基于市场对公司创新产品管线的认可，目标价上调39.9%至36.5港元，维持“跑赢行业”评级。
中金公司发表研究报告指，三生制药上半年收入43.56亿元，股东应占净利润按年增长24.6%至13.58亿元，经调整净利润按年增长2.1%至11.36亿元，符合市场预期。考虑到业务发展成果带来的收入确认，该行将2025年及26年净利润预测分别上调186.5%和138.3%，至62.49亿元及56.64亿元；基于市场对公司创新产品管线的认可，目标价上调39.9%至36.5港元，维持“跑赢行业”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.